BioSpace News Archive

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces study results showing patients treated with just its REGENETEN Bioinductive Implant for partial-thickness rotator cuff tears (>3mm) experienced significantly improved shoulder function during early recovery compared to patients receiving a REGENETEN Implant plus traditional surgical repair.

Mirimus, Inc. today announced a strategic collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the development of RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.

Agilent Technologies Inc. (NYSE: A) will release third-quarter fiscal year 2021 financial results after the stock market closes on Tuesday, August 17.

Dicerna Pharmaceuticals, Inc. today announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0 and 6.

Surface Ophthalmics, Inc. today announced it has secured gross proceeds of approximately $25 million in a private placement of preferred stock, at a purchase price of $4.50 per share.

Oramed Pharmaceuticals Inc. today announced several updates for its majority-owned company Oravax Medical Inc.

The worldwide pharmaceutical industry is experiencing notable growth in research and development activities.

bluebird bio, Inc. announced that the European Commission has granted marketing authorization of SKYSONA™, a one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen -matched sibling hematopoietic stem cell donor is not available.

Kurin Inc., the inventor and manufacturer of 510-cleared Kurin® blood culture collection sets, announced that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced it has granted an inducement award to the company’s newly appointed Chief Commercial Officer, M. Maria Törnsén, under an inducement plan adopted by its board of directors.